| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| AeroGen, Inc. |
| 1310 Orleans Drive, Sunnyvale, CA 94089 * (408) 543-2400 |
| Business Description | The company specializes in the development, manufacture and commercialization of products for the controlled delivery of drugs to the lungs, which is called pulmonary drug delivery. |
| Offering Information Company has | |||
| Trading As | AEGN (NASNTL) | Industry | Manufacturing (SIC 3845) |
| Type of Stock Offered | Common Shares | Filing Date | 8/25/00 |
| Domestic Shares Offered | 3,600,000 | Offer Date | 11/9/00 |
| Foreign Shares Offered | 0 | Filing Range | $13.00 - $15.00 |
| Company Shares | 3,600,000 | Offer Price | $12.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.840 |
| Gross Proceeds | $43,200,000 | Selling | $0.500 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 19,376,702 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | ||
| Revenues | - | - | 0.328 | 0.086 | 0.468 | 0.000 | 3.568 |
| Income from Oper. | - | - | -5.142 | -5.907 | -9.518 | -4.371 | -9.256 |
| Net Income | - | - | -5.055 | -5.562 | -8.968 | -4.068 | -9.425 |
| E.P.S | - | - | -1.140 | -1.160 | -1.650 | -0.780 | -1.460 |
| Revenue Growth (%) | - | - | -73.78 | 444.186 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.75 | -3.78 | -5.04 | ||||
| Cash Flow - Inv. | -6.66 | -7.38 | -5.55 | ||||
| Cash Flow - Fin. | -2.67 | -0.15 | 4.90 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 12.23 | Current Assets | 9.20 | Current Ratio | 4.32 |
| Total Liab. | 44.30 | Current Liab. | 2.13 | Debt Ratio | 362.30% |
| Total Equity | -32.07 | Working Cap. | 7.07 | Debt to Equity Ratio | - |
| Cash | 7.24 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research, development and clinical activities, manufacturing and commercialization of existing and future products, capital expenditures and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Stroock & Stroock & Lavan |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| U S Venture Partners affiliated entities | ||
| MF Private Capital, Inc. | ||
| InterWest Partners affiliated entities | ||
| CMEA | ||
| Advent Partners, L.P. affiliated entities | ||
| Note: represents ownership of 5% or more prior to the offering. | ||